Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052
October 03, 2022 08:30 ET
|
Prometheus Biosciences
- PRA052 is a monoclonal antibody blocking CD30 ligand that has a pleiotropic effect on both innate and adaptive immunity and targets a pathway that is distinct from TNF - - PRA052 is the second...
Prometheus Biosciences to Participate at September Healthcare Conferences
August 31, 2022 16:00 ET
|
Prometheus Biosciences
SAN DIEGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
August 11, 2022 16:00 ET
|
Prometheus Biosciences
- Both topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results expected concurrently in 4Q 2022 - - Bioavailability greater than 80% achieved upon completion of PRA023 subcutaneous bridging...
Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022
July 18, 2022 16:00 ET
|
Prometheus Biosciences
- The event will feature Prometheus management and key opinion leader presentations on PR600 target unveiling, scientific rationale, and corresponding therapeutic candidate, PRA052 - -...
Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis
July 18, 2022 08:00 ET
|
Prometheus Biosciences
- Global Phase 2 placebo-controlled trial enrolled twice as fast as the industry average, establishing a roadmap for future studies - - Enrollment initiated in Cohort 2 of CDx+ patients to evaluate...
Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies
June 08, 2022 08:00 ET
|
Prometheus Biosciences
- Enrollment completed ahead of schedule for APOLLO-CD Phase 2a study of PRA023 in Crohn’s disease patients - - ARTEMIS-UC Phase 2 Cohort 1 enrollment on track with completion expected 3Q 2022 - -...
Prometheus Biosciences to Participate at the Jefferies Healthcare Conference
May 26, 2022 08:00 ET
|
Prometheus Biosciences
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
May 12, 2022 16:01 ET
|
Prometheus Biosciences
- Advanced and expanded development of PRA023 across three immune-mediated indications - - Topline results from ARTEMIS-UC and APOLLO-CD Phase 2 studies on track for fourth quarter 2022 - -...
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
March 30, 2022 08:00 ET
|
Prometheus Biosciences
- First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways - - ATHENA-SSc-ILD Phase 2 topline results expected first-half 2024 - - FDA has...
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Progress
March 09, 2022 16:01 ET
|
Prometheus Biosciences
- Topline results for ongoing Phase 2 clinical trial in ulcerative colitis and Phase 2a trial in Crohn’s disease expected in fourth quarter 2022 - - Phase 2 trial in Systemic Sclerosis-Associated...